Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics-Reference-Cited by-同舟云学术

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

Published:2018-09 Issue: Volume:203 Page:30-38
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Green Jennifer B.,Hernandez Adrian F.,D’Agostino Ralph B.,Granger Chris B.,Janmohamed Salim,Jones Nigel P.,Leiter Lawrence A.,Noronha Drusilla,Russell Rachael,Sigmon Kristina,Del Prato Stefano,McMurray John J.V.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

2. Standards of medical care in diabetes—2017;American Diabetes Association;Diabetes Care,2017

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

5. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of dipeptidyl peptidase-4 inhibitors on cardiac structure and function using cardiac magnetic resonance: a meta-analysis of clinical studies;Frontiers in Endocrinology;2024-09-11

2. Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care;Biomedicines;2024-09-07

3. The use of composite endpoints in cardiovascular outcome trials for diabetes: A review of 22 randomized clinical trials published since 2008;Diabetes, Obesity and Metabolism;2024-09-02

4. GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know;NEUROSURG PRACT;2024

5. GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors;JACC: Heart Failure;2024-08